Zentalis Pharmaceuticals, Inc.
ZNTL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$165,867 | -$292,191 | -$237,113 | -$166,093 |
| Dep. & Amort. | $1,289 | $1,389 | $1,426 | $544 |
| Deferred Tax | $0 | -$853 | -$769 | -$2,510 |
| Stock-Based Comp. | $67,269 | $54,822 | $46,840 | $35,737 |
| Change in WC | -$16,540 | $5,864 | $13,252 | $16,605 |
| Other Non-Cash | -$57,011 | $23,147 | $12,613 | -$38,376 |
| Operating Cash Flow | -$170,860 | -$207,822 | -$163,751 | -$154,093 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$221 | -$583 | -$2,548 | -$6,107 |
| Net Acquisitions | $65 | $0 | $112 | -$14,320 |
| Inv. Purchases | -$127,962 | -$549,182 | -$533,161 | -$363,508 |
| Inv. Sales/Matur. | $304,679 | $505,307 | $421,529 | $365,820 |
| Other Inv. Act. | $0 | $0 | -$112 | $0 |
| Investing Cash Flow | $176,561 | -$44,458 | -$114,180 | -$18,115 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $349 | $237,303 | $261,043 | $179,667 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$241 | $0 | $0 | -$1,146 |
| Financing Cash Flow | $108 | $237,303 | $261,043 | $178,521 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $5,809 | -$14,977 | -$16,888 | $6,313 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $30,719 | $45,696 | $62,584 | $56,271 |
| End Cash | $36,528 | $30,719 | $45,696 | $62,584 |
| Free Cash Flow | -$171,081 | -$208,405 | -$166,299 | -$160,200 |